Floatz logo

PITTSBURGH COMPOUND B UNLABELLED

MS (Multiple Sclerosis)

Yale UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

182 Active assets in the MS (Multiple Sclerosis) cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB

View all 50 →

Same molecule, other indications

PITTSBURGH COMPOUND B UNLABELLED is also rated in:

vascular dementiaDormant
BB
Indicative ·
70 / 100
View asset →
vascular dementiaDormant
BB
Indicative ·
65 / 100
View asset →
Alzheimer diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →